Inhibition of Serotonin Synthesis May Have Antitumor Activity? Long-Term Efficacy in a Patient with Gastrointestinal Neuroendocrine Tumor.
Journal
The oncologist
ISSN: 1549-490X
Titre abrégé: Oncologist
Pays: England
ID NLM: 9607837
Informations de publication
Date de publication:
07 2019
07 2019
Historique:
received:
12
11
2018
accepted:
20
02
2019
pubmed:
17
3
2019
medline:
1
7
2020
entrez:
17
3
2019
Statut:
ppublish
Résumé
In this article, we propose, based on a clinical case, the potential antitumor effect related to the inhibition of serotonin in neuroendocrine tumors (NETs). Currently, the only drug that exists for the symptomatic treatment of carcinoid syndrome refractory to somatostatin analogues is telotristat, based on its pivotal study, the TELESTAR trial. Based on the existing preclinical rationale, it seems that the inhibition of serotonin may have an antitumoral role in NETs. Briefly, serotonin may act as an autocrine growth factor of NETs, and it may also play an immunomodulatory role by enhancing macrophage polarization to an immunotolerant M2 phenotype. To our knowledge, this rationale for the possible antitumor effect of serotonin in NETs has not yet been published in the literature.
Identifiants
pubmed: 30877189
pii: theoncologist.2018-0776
doi: 10.1634/theoncologist.2018-0776
pmc: PMC6656452
doi:
Substances chimiques
Serotonin Antagonists
0
Types de publication
Case Reports
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e597-e599Informations de copyright
© AlphaMed Press 2019.
Déclaration de conflit d'intérêts
Disclosures of potential conflicts of interest may be found at the end of this article.
Références
Gastroenterology. 2005 May;128(6):1717-51
pubmed: 15887161
Cancer. 2009 Nov 1;115(21):4934-45
pubmed: 19634160
Pancreas. 2012 Apr;41(3):461-6
pubmed: 22422138
Neuroendocrinology. 2012;96(3):173-87
pubmed: 22538498
J Immunol. 2013 Mar 1;190(5):2301-10
pubmed: 23355731
Oncologist. 2016 Jun;21(6):701-7
pubmed: 27107003
J Clin Oncol. 2017 Jan;35(1):14-23
pubmed: 27918724
Nat Rev Clin Oncol. 2017 Jul;14(7):399-416
pubmed: 28117416
Lancet Oncol. 2017 Apr;18(4):525-534
pubmed: 28238592